These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 11248068)
1. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Gilewski T; Ragupathi G; Bhuta S; Williams LJ; Musselli C; Zhang XF; Bornmann WG; Spassova M; Bencsath KP; Panageas KS; Chin J; Hudis CA; Norton L; Houghton AN; Livingston PO; Danishefsky SJ Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3270-5. PubMed ID: 11248068 [TBL] [Abstract][Full Text] [Related]
2. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Slovin SF; Ragupathi G; Adluri S; Ungers G; Terry K; Kim S; Spassova M; Bornmann WG; Fazzari M; Dantis L; Olkiewicz K; Lloyd KO; Livingston PO; Danishefsky SJ; Scher HI Proc Natl Acad Sci U S A; 1999 May; 96(10):5710-5. PubMed ID: 10318949 [TBL] [Abstract][Full Text] [Related]
3. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545 [TBL] [Abstract][Full Text] [Related]
5. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Wang ZG; Williams LJ; Zhang XF; Zatorski A; Kudryashov V; Ragupathi G; Spassova M; Bornmann W; Slovin SF; Scher HI; Livingston PO; Lloyd KO; Danishefsky SJ Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2719-24. PubMed ID: 10716997 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887 [TBL] [Abstract][Full Text] [Related]
8. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361 [TBL] [Abstract][Full Text] [Related]
9. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967 [TBL] [Abstract][Full Text] [Related]
10. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999 [TBL] [Abstract][Full Text] [Related]
11. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. Huang CS; Yu AL; Tseng LM; Chow LWC; Hou MF; Hurvitz SA; Schwab RB; L Murray J; Chang HK; Chang HT; Chen SC; Kim SB; Hung JT; Ueng SH; Lee SH; Chen CC; Rugo HS J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718986 [TBL] [Abstract][Full Text] [Related]
12. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341 [TBL] [Abstract][Full Text] [Related]
14. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Krug LM; Ragupathi G; Hood C; Kris MG; Miller VA; Allen JR; Keding SJ; Danishefsky SJ; Gomez J; Tyson L; Pizzo B; Baez V; Livingston PO Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6094-100. PubMed ID: 15447995 [TBL] [Abstract][Full Text] [Related]
15. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785 [TBL] [Abstract][Full Text] [Related]
16. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062 [TBL] [Abstract][Full Text] [Related]
17. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877 [TBL] [Abstract][Full Text] [Related]
18. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456 [TBL] [Abstract][Full Text] [Related]
19. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710 [TBL] [Abstract][Full Text] [Related]
20. Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate. Kudryashov V; Ragupathi G; Kim IJ; Breimer ME; Danishefsky SJ; Livingston PO; Lloyd KO Glycoconj J; 1998 Mar; 15(3):243-9. PubMed ID: 9579801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]